**Moderne COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group**

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.

- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

### Children who turn from age 5 to age 6 years

**Recommended:** Children who started a primary series and turned from age 5 to age 6 years before completion of the series should receive:

- **Dose 1 (Age 5):**
  - 0.25 mL (25 mcg) of the monovalent product authorized for children ages 6 months–5 years (dark blue cap/magenta label border)

- **Dose 2 (Age 6):**
  - 0.50 mL (50 mcg) of the monovalent product authorized for children ages 6–11 years (dark blue cap/purple label border)

**Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

**Either dose may be:**

- 0.25 mL (25 mcg) of the monovalent product authorized for children ages 6 months–5 years (dark blue cap/magenta label border), or
- 0.50 mL (50 mcg) of the monovalent product authorized for children ages 6–11 years (dark blue cap/purple label border)

**Note:** Vial icons with an "M" indicate monovalent vaccine and those with a "B" indicate bivalent vaccine.
Special Situations for COVID-19 Vaccination of Children and Adolescents
Age Transitions and Interchangeability

Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (continued)

### Children who turn from age 11 years to 12 years

**Recommended:** Children who started a primary series and turned from age 11 to age 12 years before completion of the series should receive:

- **Dose 1 (Age 11):**
  - 0.50 mL (50 mcg) of the monovalent product authorized for children ages 6–11 years (dark blue cap/purple label border)

- **Dose 2 (Age 12):**
  - 0.50 mL (100 mcg) of the monovalent product authorized for children ages 12 years and older (red cap/light blue label border)

- **4-8 weeks**

**Child turns 12**

**Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Either dose may be:

- 0.50 mL (50 mcg) of the monovalent product authorized for children ages 6–11 years (dark blue cap/purple label border), OR
- 0.50 mL (100 mcg) of the monovalent product authorized for children ages 12–17 years (red cap/light blue label border)

**Dose 1: Age 11**

**Dose 2: Age 12**

**OR**

**Note:** Vial icons with an "M" indicate monovalent vaccine and those with a "B" indicate bivalent vaccine.
**Pfizer-BioNTech COVID-19 Vaccine for Children who Transition from Age 4 Years to Age 5 Years**

FDA emergency use authorization (EUA) requires children who will turn from age 4 years to 5 years during the primary series to complete the series they start, either:

- The 3-dose primary series recommended for children ages 6 months–4 years or
- The 2-dose primary series recommended for children ages 5 years–11 years

Because no other dosing options are authorized for this age transition, CDC’s standard guidance to administer the age-appropriate vaccine product and dosage based on age on the day of vaccination does **NOT** apply.

### Children who turn from age 4 to age 5 years

**Authorized:** Children who turn from age 4 years to 5 years between any doses in the primary series should receive either:

- A 3-dose primary series using the:
  - Monovalent Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years (maroon cap and label border) for doses 1 and 2 and
  - Bivalent Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 6 months–4 years (maroon cap and label border) for dose 3

**Dose 1:**
0.20 mL (3 mcg) of the monovalent product authorized for children ages 6 months–4 years (maroon cap and label border)

**Dose 2:**
0.20 mL (3 mcg) of the monovalent product authorized for children ages 6 months–4 years (maroon cap and label border)

**Dose 3:**
0.20 mL (3 mcg) of the bivalent product authorized for children ages 6 months–4 years (maroon cap and label border)

**Or**

- A 2-dose primary series using the monovalent Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border)

**Dose 1:**
0.20 mL (10 mcg) of the monovalent product authorized for children ages 5–11 years (orange cap and label border)

**Dose 2:**
0.20 mL (10 mcg) of the monovalent product authorized for children ages 5–11 years (orange cap and label border)

**Note:** Vial icons with an "M" indicate monovalent vaccine and those with a "B" indicate bivalent vaccine.
**Recommended**: Children who started a primary series and turned from age 11 to age 12 years before completion of the series should receive:

**Dose 1 (Age 11):**
0.20 mL (10 mcg) of the monovalent product authorized for children ages 5–11 years (orange cap and label border)  

**Dose 2 (Age 12):**
0.30 mL (30 mcg) of the monovalent product authorized for children ages 12–17 years (gray cap and label border)

**Acceptable**: If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Either dose may be:
- 0.20 mL (10 mcg) of the monovalent product authorized for children ages 5–11 years (orange cap and label border), or
- 0.30 mL (30 mcg) of the monovalent product authorized for children ages 12–17 years (gray cap and label border)

Note: Vial icons with an "M" indicate monovalent vaccine and those with a "B" indicate bivalent vaccine.
Interchangeability of Moderna and Pfizer-BioNTech COVID-19 vaccines

COVID-19 vaccine from the same manufacturer should be used for the primary series. If a different manufacturer is administered, follow the guidance below:

- If a dose of the age-appropriate product from BOTH Moderna and Pfizer-BioNTech COVID-19 is given, count both doses if the recommended interval between doses has been met.
  - If ages 6 months through 4 years, a third dose of either a monovalent Moderna vaccine or bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the series. See examples.
  - Repeating doses is not recommended.

This guidance applies to:
- All eligible children, including those who are moderately or severely immunocompromised.
- Vaccines from both manufacturers, regardless which vaccine was given first.

Examples:

**Vaccination history:** 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.

1. Moderna → at least 4 weeks → Pfizer-BioNTech
2. Pfizer-BioNTech → at least 8 weeks → Pfizer-BioNTech
3. OR
4. Moderna → at least 4 weeks → Moderna

**Primary series complete**